Biogen Idec’s ALS drug Failed Final Clinical Trial

.

Biogen Idec’s ALS drug Failed Final Clinical Trial

As per reports, it has been recently revealed that Biogen Idec was unable to get through the last clinical trial of its ALS drug. Researchers have acknowledged the loss by saying that it was not only shocking but discouraging as well.

Dr. Robert Brown, who is an ALS researcher, was of the view that they have worked hard on the drug, but they failed a crucial test. However, this does not mean that no more research will take as the disease needs an effective treatment.

While talking about the last and final clinical trial, which could not attain success, Brown said that they had enrolled 943 people, who were suffering from amyotrophic lateral sclerosis. They were enrolled to test the efficacy of their once-promising dexpramipexole drug.

After carrying out the study, Brown said that they did not find any sort of benefit from the drug. And, then only, they decided to halt the programme. "While these results were not what we expected, we hope this data will provide a foundation for future ALS research", said Dr. Douglas Kerr, who is the director of neurodegeneration clinical research at Biogen.

The failure does not mark an end to the research, said Kerr, as they still have been working on it.

 


Latest News

Good News for the Diabetic: FDA Approved Mobile Medical Application for Sharing
Fifth Death Related to Flu in Bay Area; The  First in Napa County
Ship Industry
For Bill Erbey Its Time to Pay Back
Union Organizers Files Lawsuit Against American Airlines
Venus In Past Had Vast Oceans of Liquid Carbon Dioxide, Say Researchers
Bill and Melinda Gates Have Long term Charity Plans but Now It’s Time for Super
Wynn Everett Casino Design Have Alterations with More luxury rooms and Lesser Pa
Alert Issued after Adult Film Actor became infected with HIV
Out Look for Oil Future Remains Weak Though Brent Crude Moves Above $48
BOJ Trimmed Its Inflation Forecast and Expanded Loan Scheme Aimed at Boosting Le
Layoff Reports at DreamWorks Animation following Changes in Higher Management Le